[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Qianfoshan Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":639},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,42,0,25,[9,46,70,107,135,162,191,210,237,258,281,311,334,359,382,410,431,454,480,506,523,549,572,593,612],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100651200","real-world-effectiveness-of-tezepelumab-in-allergic-bronchopulmonary-aspergillosis-100651200",false,"NCT07757841","Real-World Effectiveness of Tezepelumab in Allergic Bronchopulmonary Aspergillosis","Effectiveness and Safety of Tezepelumab in Allergic Bronchopulmonary Aspergillosis (ABPA): a Prospective Study of Real-world Experience","Inclusion Criteria:\n\nFemale and Male patients aged 18-75 years inclusively at the time of Visit 1 with a physician diagnosis of Allergic Bronchopulmonary Aspergillosis has met the ISHAM Working Group Diagnostic Criteria for ABPA:\n\nPredisposing condition: Bronchial asthma Obligatory criteria (both should be present) Type I aspergillus skin test positive (immediate cutaneous hypersensitivity Aspergillus antigen) or elevated IgE level against Aspergillus fumigatus (Af) Aspergillus niger or Aspergillus flavus may be eligible provided antigen-specific IgE and IgG measurements are available for use. Elevated total IgE levels (\\>1,000IU\u002FmL)\\* Other criteria (at least two of three)\n\nPresence of precipitating or IgG antibodies against Af in serum Radiographic pulmonary opacities consistent with ABPA Total eosinophil count \\>500 cells\u002FuL in steroid naïve patients (may be historical)\n\n(if the patient meets all other criteria, an IgE value \\\u003C1,000 IU\u002FmL may be acceptable) Severe chronic asthma (for at least 12 months) requiring treatment with high dose ICS plus asthma controller prior to Visit 1\n\nOther acceptable asthma controllers include long acting bronchodilators (e.g. a long acting beta-agonist (LABA) or long-acting muscarinic antagonists (LAMA)), a leukotriene inhibitor, theophylline preparations and\u002For maintenance OCS (daily or every other day OCS requirement in order to maintain asthma control Documented current treatment with high daily doses of ICS ( \\>500ug of FP equivalent) plus at least one other asthma controller for at least 3 months prior to Visit 1\n\nFor ICS\u002FLABA combination preparation, highest-strength maintenance doses approved in the U.S. will meet this criterion If the ICS and the other asthma controller therapies are given by separate inhalers, then the patient must be on a high daily ICS dose for 3 months prior to entering the study. History of at least 2 asthma exacerbations while on ICS plus another asthma controller (see inclusion criterion 2 for examples) that required treatment with systemic corticosteroids (IM, IV, or oral) in the 12 months prior to Visit 1. For patients receiving oral corticosteroids as a maintenance therapy, an exacerbation is defined as a temporary increase of their maintenance dose for a minimum of 3 days. Weight \\> 40kg\n\nExclusion Criteria:\n\nClinically important pulmonary disease other than asthma with allergic bronchopulmonary aspergillosis (i.e., chronic obstructive pulmonary disease (COPD), cystic fibrosis, sarcoidosis, and pulmonary fibrosis).\n\nHistory of anaphylaxis to any biologic therapy. Known history of allergy or hypersensitivity reaction to tezepelumab or any of its components.\n\nCurrently pregnant, breastfeeding, or lactating women. Concurrent enrollment in another interventional or post-authorization safety study, unless it is observational.","ALL","18 Years","75 Years",{"count":21,"type":22},10,"ESTIMATED","INTERVENTIONAL",[25],"NA","An open-label study will evaluate effects of Tezepelumab in the treatment of severe asthma in patients with allergic bronchopulmonary aspergillosis",[28,29,30],"Allergic Bronchopulmonary Aspergillosis","Severe Asthma","ABPA",[30,32],"Tezepelumab","NOT_YET_RECRUITING","2026-08-10",{"date":36,"type":37},"2026-08-11","ACTUAL",{"date":39,"type":22},"2026-09-01",{"date":41,"type":22},"2027-12-31",{"name":43,"class":44},"Qianfoshan Hospital","OTHER",1,{"id":47,"slug":48,"hasResults":12,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":67,"leadSponsor":69,"locationsCount":4},"100651360","phase-4-afentanil-and-remifentanil-for-anesthesia-quality-and-recovery-100651360","NCT07761312","Afentanil and Remifentanil for Anesthesia Quality and Recovery","Comparison of Anesthetic Quality and Recovery Between Afentanil and Remifentanil: A Multicenter, Randomized, Double-Blind, Controlled, Non-Inferiority Trial","Inclusion Criteria:(1) Age between 18 and 65 years, with no gender restriction; (2) BMI ≥ 18 kg\u002Fm²; (3) ASA classification I-III; (4) Elective surgeries that are not related to the chest or brain, with an anticipated duration of 60-240 minutes; (5) Anticipated blood loss \\\u003C 500 mL; (6) Voluntary consent to sign the Informed Consent Form.\n\nExclusion Criteria:(1) Abuse or long-term use of opioid medications; (2) Severe hepatic and renal dysfunction (ALT\u002FAST \\> 2×ULN, Cr \\> 176 μmol\u002FL); (3) Serious cardiovascular diseases, including but not limited to: Severe cardiac arrhythmias or conduction abnormalities, such as ventricular arrhythmias requiring clinical intervention, second- or third-degree atrioventricular block, or uncontrolled atrial fibrillation; a history of acute myocardial infarction, unstable angina pectoris within the past 6 months, or having undergone coronary stenting or coronary artery bypass surgery.\n\nCongestive heart failure classified as NYHA Class II or above, or left ventricular ejection fraction (LVEF) \\\u003C 50%.\n\n(4) A history of cerebrovascular accidents (including ischemic and hemorrhagic strokes) or transient ischemic attacks within the past 6 months; (5) Uncontrolled severe hypertension: resting systolic blood pressure ≥ 160 mmHg and\u002For diastolic blood pressure ≥ 100 mmHg (confirmed by repeated measurements); (6) Symptomatic aortic dissection, or lower limb arterial occlusion requiring treatment.(4) Severe blood system disorders, including but not limited to severe anemia, aplastic anemia, acute leukemia, thrombotic thrombocytopenic purpura, etc.\n\n(5) Difficulty in predicting airway management; (6) Pregnancy or lactation; (7) Allergy to opioids\u002Fpropropofol\u002Feggs\u002Fsoybeans; (8) Participation in other clinical trials within the past 3 months.\n\n\\-","65 Years",{"count":55,"type":22},990,[57],"PHASE4","The goal of this clinical trial is to compare two commonly used opioid pain medications-alfentanil and remifentanil-during general anesthesia for surgery, and to find out whether alfentanil is as good as (not worse than) remifentanil in keeping patients stable (steady blood pressure and heart rate) and adequately pain-free during the operation. The study will enroll adults aged 18-65 years who are in good to fair health (ASA class I-III) and are scheduled for elective non-cardiac, non-brain surgery lasting 1 to 4 hours with expected blood loss under 500 mL.\n\nThe main questions it aims to answer are:\n\nHow often do patients need extra painkillers or blood-pressure medications during surgery (a \"rescue event\") when receiving alfentanil compared with remifentanil?\n\nHow quickly do patients wake up, breathe on their own, and get discharged from the recovery room after the operation?\n\nDo patients experience differences in pain levels, nausea, vomiting, or thinking\u002Fmemory problems in the days after surgery?\n\nIf there is a comparison group: Researchers will compare the alfentanil group with the remifentanil group to see if the rate of rescue events with alfentanil is not more than 8% higher than with remifentanil (the non-inferiority margin). Both groups will receive the same standard anesthetic (propofol and muscle relaxants) and the same postoperative pain management; only the study opioid differs.\n\nParticipants will:\n\nSign an informed consent form and undergo screening tests, including blood work, physical exam, and medical history review.\n\nBe randomly assigned (like a coin flip) to receive either alfentanil or remifentanil during their operation, with the drug given through an IV. Neither the patient nor the care team will know which drug is given until after the study is completed.\n\nHave their blood pressure, heart rate, breathing, and brain activity (using BIS monitors to measure depth of anesthesia) continuously tracked during surgery.\n\nAfter surgery, be followed for up to 3 days, during which they will be asked to rate their pain (using a simple 0-10 scale) and complete a short memory\u002Fthinking test (MMSE) at set times.\n\nProvide small blood samples before, right after, and 24 hours after surgery to measure stress hormones and inflammation markers.\n\nThis study will involve about 990 patients across multiple hospitals and will take about 2 years to complete. The results will help doctors choose the best opioid for safer, smoother surgeries and faster recovery.",[60],"Anesthesia Recovery Period ； Postoperative Pain； Hemodynamic Stability During Surgery",[62],"Alfentanil；Remifentanil；Propofol TIVA；Non-inferiority；Hemodynamics；Postoperative pain；Recovery；Cognitive function","2026-08-08",{"date":65,"type":37},"2026-08-12",{"date":39,"type":22},{"date":68,"type":22},"2027-09-30",{"name":43,"class":44},{"id":71,"slug":72,"hasResults":12,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":12,"sex":17,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":23,"phases":81,"briefSummary":83,"conditions":84,"keywords":87,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":45},"100648248","phase-1-zr001-chemogenetics-gene-therapy-study-in-patients-with-parkinsons-disease-100648248","NCT07718659","ZR001 Chemogenetics Gene Therapy Study in Patients With Parkinson's Disease","An Open-label, Single Arm, Dose-Escalation Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of ZR001, a Gene Therapy Based on Chemogenetics, for the Treatment of Parkinson's Disease","Inclusion Criteria:\n\n* Participants who meet all of the following criteria are eligible for enrollment:\n\n  1. Age ≥40 and ≤70 years (at the time of signing the informed consent), any gender.\n  2. Diagnosed with Parkinson's disease according to the Diagnostic Criteria for Parkinson's Disease in China (2016 edition).\n  3. Modified Hoehn \\& Yahr stage between 2.5 and 4.\n  4. History of Parkinson's disease for at least 5 years but less than 15 years.\n  5. Moderate to severe MDS-UPDRS Part III score in the off period, and improvement rate ≥30% after acute levodopa stress test.\n  6. Clinically stable symptoms and stable types and doses of anti-Parkinsonian medications within 3 months prior to enrollment.\n  7. Agree to provide biological samples required for the study (e.g., blood, urine).\n  8. Consent to hospitalization for intraparenchymal drug injection surgery.\n  9. Male or female participants of childbearing potential agree to use effective contraceptive methods (oral contraceptives are prohibited) from the time of signing the informed consent until at least 6 months after discontinuing clozapine.\n  10. Participants or their stable caregivers are able to understand and willing to comply with the study requirements and procedures, voluntarily participate, and sign the informed consent. If a caregiver is present, they must accompany the participant to study visits and assist the investigator in completing relevant scale assessments.\n\nExclusion Criteria:\n\n* Participants who meet any of the following criteria will be excluded from this study:\n\n  1. Have participated in or are currently participating in other clinical studies of PD drugs or other AAV gene therapy or cell therapy.\n  2. Presence of other severe psychiatric disorders (e.g., severe depression, schizophrenia, etc.).\n  3. Previous adverse reactions to clozapine, such as agranulocytosis or severe neutropenia.\n  4. Participants with known allergic constitution, including allergy or hypersensitivity to clozapine, prednisone acetate, other glucocorticoids, their excipients, or local anesthetics.\n  5. History of alcohol or drug abuse within the past 2 years.\n  6. Participants requiring invasive or non-invasive ventilatory support.\n  7. Serum AAV binding antibody titer \\>1:2000.\n  8. Presence of clinically significant laboratory abnormalities as assessed by the investigator: alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), total bilirubin; creatinine, hemoglobin (Hb), prothrombin time (PT), activated partial thromboplastin time (APTT), fasting blood glucose, platelets (PLT).\n  9. Presence of liver disease, heart disease, kidney disease or history thereof, which, in the investigator's assessment, may pose surgical or drug-related risks to the participant.\n  10. Suffering from autoimmune diseases or immunocompromised status requiring hormone or immunosuppressive therapy, which, in the investigator's assessment, may pose surgical or drug-related risks.\n  11. Suffering from other severe systemic diseases (e.g., cor pulmonale, moderate-to-severe asthma, etc.) that, in the investigator's assessment, may pose surgical or drug-related risks.\n  12. In the investigator's assessment, the participant has contraindications to anesthesia or surgery and is unsuitable for intraparenchymal administration, or other special circumstances.\n  13. Positive for human immunodeficiency virus antibody, hepatitis B surface antigen, hepatitis C antibody, syphilis antibody, active TORCH virus infection, or active Epstein-Barr virus infection.\n  14. Concomitant use of any of the following medications within 90 days prior to administration, or planned immunosuppressive therapy (cyclosporine, tacrolimus, methotrexate, cyclophosphamide, intravenous immunoglobulin, rituximab) within 6 months after start of the trial, except for prophylactic medications specified in the protocol.\n  15. Pregnant or breastfeeding women, or those planning to become pregnant.\n  16. Other conditions that, in the investigator's opinion, make the participant unsuitable for participation in this study.","40 Years","70 Years",{"count":80,"type":22},8,[82],"PHASE1","This study aims to evaluate the safety, tolerability, and preliminary efficacy of ZR001, a novel chemogenetic gene therapy product, in patients with moderately advanced Parkinson's disease (PD). ZR001 is administered via stereotactic injection into the bilateral substantia nigra, followed by postoperative ultra-low-dose clozapine to activate the transduced direct pathway, with the goal of improving motor symptoms of Parkinson's disease.",[85,86],"Parkinson's Disease (PD)","Parkinsonian Disorders",[88,89,90,91,92,93,94,95,96,97,98],"AAV","DREADD","PD","D1-MSN","Gene Therapy","Chemogenetics","Parkinson's Disease","Clozapine","Central Nervous System Diseases","Movement Disorders","Neurodegenerative Diseases","2026-07-17",{"date":101,"type":37},"2026-07-22",{"date":103,"type":22},"2026-12-01",{"date":105,"type":22},"2030-12-01",{"name":43,"class":44},{"id":108,"slug":109,"hasResults":12,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":115,"targetDuration":117,"studyType":118,"phases":4,"briefSummary":119,"conditions":120,"keywords":124,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":45},"100647916","ml-based-abpa-recurrence-prediction-and-clinical-utility-100647916","NCT07714863","ML-Based ABPA Recurrence Prediction and Clinical Utility","Machine Learning-Based Prediction of Recurrence Risk in Allergic Bronchopulmonary Aspergillosis and Its Clinical Decision-Making Value: A Multicenter Study With External Validation","ABPA-ML","Inclusion Criteria:\n\n1. Aged between 18 and 80 years old.\n2. Consistent with the diagnostic consensus criteria for ABPA proposed by the ISHAM-ABPA Working Group.\n3. Patients in stable phase of ABPA: newly diagnosed treatment-naive patients or those with prior ABPA exacerbation who achieved at least 50% improvement in symptoms assessed by Likert scale or visual analogue scale (VAS) following initial therapy, accompanied by marked radiological improvement (≥50% reduction in pulmonary opacities) or a minimum 20% decline in serum total IgE level.\n\nExclusion Criteria:\n\n1. Concurrent malignant tumors or severe organ dysfunction involving the heart, brain, kidney and other vital organs.\n2. Complicated with severe underlying diseases, including active pulmonary tuberculosis, lung cancer, chronic heart failure (NYHA class Ⅳ), chronic kidney disease stage 5 (CKD 5), decompensated liver cirrhosis, etc.\n3. Immunocompromised status, such as human immunodeficiency virus (HIV) infection, long-term oral administration of glucocorticoids or immunosuppressive agents.\n4. Pregnant or breastfeeding women.\n5. Patients with missing core clinical data or incomplete medical records.",{"count":116,"type":22},200,"1 Year","OBSERVATIONAL","This multicenter bidirectional cohort study aims to develop and externally validate a machine learning model for predicting the risk of acute exacerbation within 1 year in patients with allergic bronchopulmonary aspergillosis (ABPA) during the stable phase, and further to evaluate the model's practical value in risk stratification and clinical decision-making.\n\nAll patients diagnosed with ABPA according to the ISHAM 2024 criteria will be assigned to either the acute exacerbation group or the non-exacerbation group based on whether they experience an acute exacerbation within 1 year. Enrolled participants will be randomly divided into a training set and an internal validation set. During the feature selection phase, univariate analysis, collinearity diagnostics, feature importance ranking derived from nine machine learning algorithms, and expert consensus are comprehensively applied, ultimately leading to the development of 12 independent machine learning models.\n\nModel performance is assessed using the receiver operating characteristic (ROC) curve and its area under the curve (AUC), sensitivity, specificity, F1-score, calibration curve, and decision curve analysis. In addition, external validation further enhances the credibility of the model. To improve clinical interpretability, the SHAP method is employed to quantify the contribution of each feature, and an interactive nomogram is constructed to facilitate clinical application.\n\nAll participants will be followed up for 12 months, during which regular clinical and laboratory evaluations will be performed.",[30,28,121,122,123],"Allergic Bronchopulmonary Aspergillosis (ABPA)","Acute Exacerbation","Machine Learning",[30,125,123],"Acute exacerbation","RECRUITING","2026-07-14",{"date":129,"type":37},"2026-07-20",{"date":131,"type":37},"2021-01-01",{"date":133,"type":22},"2028-12-31",{"name":43,"class":44},{"id":136,"slug":137,"hasResults":12,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":118,"phases":4,"briefSummary":145,"conditions":146,"keywords":148,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":161,"locationsCount":45},"100646535","fungal-status-and-prognosis-in-abpa-100646535","NCT07690345","Fungal Status and Prognosis in ABPA","Clinical Characteristics and Prognostic Outcomes of Allergic Bronchopulmonary Aspergillosis Patients Stratified by Fungal Microbiological Status in Sputum or Bronchoalveolar Lavage Fluid: A Multicenter Bidirectional Cohort Study","ABPAFUNGAL","Inclusion Criteria:\n\n* 1.Adult patients (≥18 years old) diagnosed with allergic bronchopulmonary aspergillosis (ABPA) according to the 2024 International Society for Human and Animal Mycology (ISHAM) diagnostic criteria.\n\n  2.Patients hospitalized during the study period in participating centers with sputum or bronchoalveolar lavage fluid (BALF) collection performed.\n\n  3.At least one mycological test performed on sputum or BALF, including fungal culture, galactomannan (GM) assay, metagenomic next-generation sequencing (mNGS), or targeted next-generation sequencing (tNGS), with clearly interpretable results (positive or negative).\n\n  4.Availability of complete and traceable clinical data, including medical history, imaging, laboratory tests, treatment records, and follow-up information, with no critical missing data.\n\n  5.Willingness to participate in follow-up and signed informed consent (for prospective participants), with good compliance for follow-up.\n\n  6.No systemic antifungal therapy or other interventions that may significantly affect mycological test results within 1 month prior to enrollment.\n\nExclusion Criteria:\n\n* 1.Coexisting pulmonary fungal infections (e.g., invasive pulmonary aspergillosis) or other confirmed non-fungal pulmonary infections.\n\n  2.Presence of other structural lung diseases, such as pulmonary tuberculosis, lung cancer, or lung abscess.\n\n  3.Severe immunodeficiency or other significant allergic pulmonary diseases that may confound the diagnosis of ABPA.\n\n  4.Absence of sputum or BALF samples, or lack of valid mycological test results. 5.Incomplete key clinical data (e.g., total IgE, Aspergillus-specific IgE\u002FIgG, imaging, or pulmonary function data) or inability to complete at least 3 months of follow-up.\n\n  6.Systemic antifungal treatment within 1 month prior to enrollment or participation in another interventional clinical trial.\n\n  7.Contraindications to bronchoscopy\u002FBAL procedures or known severe allergy to relevant reagents used in testing.",{"count":144,"type":22},114,"This multicenter bidirectional cohort study aims to investigate the clinical characteristics and prognostic outcomes of patients with allergic bronchopulmonary aspergillosis (ABPA) stratified by fungal microbiological status in sputum or bronchoalveolar lavage fluid (BALF).\n\nPatients diagnosed with ABPA according to the ISHAM 2024 criteria will be classified into fungal-positive and fungal-negative groups based on results from fungal culture, galactomannan (GM) testing, and metagenomic next-generation sequencing (mNGS) of sputum or BALF samples.\n\nThe study will compare baseline clinical features, laboratory findings, radiological characteristics, treatment response, and long-term outcomes, including acute exacerbation rate and time to first exacerbation, between the two groups.\n\nAll participants will be followed for up to 12 months with serial clinical and laboratory assessments.",[30,28,121,147],"Colonization",[30,149,150,151,152,153,154],"Aspergillus","bronchiectasis","fungal colonization","BALF","galactomannan","allergic bronchopulmonary mycosis","2026-07-07",{"date":157,"type":37},"2026-07-08",{"date":159,"type":37},"2025-07-01",{"date":133,"type":22},{"name":43,"class":44},{"id":163,"slug":164,"hasResults":12,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":169,"sex":17,"minAge":18,"maxAge":170,"enrollmentInfo":171,"targetDuration":4,"studyType":23,"phases":173,"briefSummary":174,"conditions":175,"keywords":178,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":4},"100639566","multifunctional-oropharyngeal-airway-and-hypoxemia-in-sedated-gi-endoscopy-a-multicenter-rct-100639566","NCT07623863","Multifunctional Oropharyngeal Airway and Hypoxemia in Sedated GI Endoscopy: A Multicenter RCT","Effect of a Novel Multifunctional Oropharyngeal Airway on Hypoxemia in Patients Undergoing Sedated Gastrointestinal Endoscopy: A Multicenter, Prospective, Randomized Controlled Trial","Inclusion Criteria:\n\n* Age 18-80 years;\n* BMI: 18-30 kg\u002Fm²;\n* ASA class I-II;\n* Scheduled to undergo elective sedated gastrointestinal endoscopy;\n* Willing to participate in this study and able to provide written informed consent.\n\nExclusion Criteria:\n\n* Diagnosed respiratory diseases, including asthma, bronchitis, chronic obstructive pulmonary disease (COPD), emphysema, moderate or severe obstructive sleep apnea (OSA), pulmonary embolism, pulmonary edema, lung cancer, or upper respiratory tract infection, etc.;\n* Coagulation disorders, tendency for oral\u002Fnasal bleeding, mucosal injury, or space-occupying lesions;\n* Severe cardiac insufficiency (≤4 MetS);\n* Severe renal insufficiency (acute kidney injury \\[AKI\\] or chronic kidney disease \\[CKD\\] stage 4 or higher);\n* Severe hepatic insufficiency (Child-Pugh class C or worse);\n* Planned therapeutic endoscopy (e.g., polypectomy, endoscopic mucosal resection \\[EMR\\], or other therapeutic procedures);\n* Pregnancy or breastfeeding;\n* Allergy to the study drugs;\n* Emergency surgery;\n* Daily alcohol intake ≥60 grams;\n* History of psychiatric disorders: e.g., depression, severe central nervous system depression, Parkinson's disease, basal ganglia lesions, schizophrenia, epilepsy, Alzheimer's disease;\n* Myasthenia gravis;\n* Participation in other related clinical trials within the past 3 months;\n* Refusal to participate.",true,"80 Years",{"count":172,"type":22},1518,[25],"This multicenter, prospective, randomized controlled trial aims to evaluate whether a novel multifunctional oropharyngeal airway (MOPA) reduces the incidence of hypoxemia in 1,518 adult patients (ASA I-II, aged 18-80 years) undergoing elective sedated gastrointestinal endoscopy. Patients are randomized 1:1 to receive either the MOPA (which integrates oxygen delivery, PETCO₂ monitoring, and airway support) or conventional nasal cannula with standard mouthpiece. The primary endpoint is the incidence of hypoxemia (75% ≤ SpO₂ \\\u003C 90% for \\\u003C60 seconds) during the procedure. Secondary outcomes include severe hypoxemia, hypercapnia, PETCO₂ monitoring success, airway interventions, adverse events, and satisfaction scores. The study is conducted across 29 centers in China, with centralized randomization via an EDC system, blinded outcome assessment, and statistical analysis using a two-sided alpha of 0.05 (power 90%). Results are expected to provide high-level evidence for optimizing airway management during sedated endoscopy.",[176,177],"Hypoxemia","Airway Management",[179,180,181,182],"Novel multifunctional oropharyngeal airway","Capnography \u002F PETCO₂ monitoring","Airway management","Randomized controlled trial","2026-05-28",{"date":185,"type":37},"2026-06-03",{"date":187,"type":22},"2026-06-01",{"date":189,"type":22},"2028-06-01",{"name":43,"class":44},{"id":192,"slug":193,"hasResults":12,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":4,"eligibilityCriteria":197,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":170,"enrollmentInfo":198,"targetDuration":4,"studyType":118,"phases":4,"briefSummary":200,"conditions":201,"keywords":205,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":206,"startDateStruct":207,"completionDateStruct":208,"leadSponsor":209,"locationsCount":45},"100638551","multi-omics-inflammatory-phenotype-for-abpa-recurrence-risk-prediction-100638551","NCT07611838","Multi-Omics Inflammatory Phenotype for ABPA Recurrence Risk Prediction","Multi-Omics Data-Derived Inflammatory Phenotype for ABPA Recurrence Risk Prediction: A Multicenter Study","Inclusion Criteria:\n\n* Female and Male patients aged 18-80 years\n* diagnosis of Allergic Bronchopulmonary Aspergillosis ABPA accroding to the 2024 ISHAM Working Group Diagnostic Criteria\n\nExclusion Criteria:\n\n* Patients with malignant tumors or severe organ dysfunction (e.g., cardiac, cerebral, renal, etc.)\n* Patients with severe comorbidities, including active pulmonary tuberculosis, lung cancer, chronic heart failure (NYHA class Ⅳ), chronic kidney disease (CKD stage 5), decompensated cirrhosis, etc.\n* Patients with immunosuppressive status, such as HIV infection, long-term use of oral corticosteroids or immunosuppressive agents.\n* Pregnant or lactating women.\n* Patients with missing key data or incomplete medical records.",{"count":199,"type":22},300,"To develop and externally validate a machine learning model for predicting the 1-year risk of relapse in patients with stable ABPA, and to further evaluate its value in risk stratification and clinical decision-making.",[121,123,202,203,204],"Multi-omics","Multicenter Study","Relapse",[28,204,123,203,202],{"date":187,"type":37},{"date":131,"type":37},{"date":133,"type":22},{"name":43,"class":44},{"id":211,"slug":212,"hasResults":12,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":4,"eligibilityCriteria":216,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":217,"targetDuration":4,"studyType":23,"phases":219,"briefSummary":220,"conditions":221,"keywords":224,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":4},"100640937","phase-1-opioid-free-anesthesia-and-postoperative-delirium-100640937","NCT07603596","Opioid-free Anesthesia and Postoperative Delirium","Effect of Opioid-free Anesthesia on Postoperative Delirium in Elderly Patients Undergoing Gastrointestinal Surgery","Inclusion Criteria:\n\n1. Patients who plan to undergo elective gastrointestinal surgery under general anaesthesia\n2. Age ≥65 years\n3. American Society of Anaesthesiologists (ASA) grade I-III\n4. Body mass index (BMI) of 18.0-30.0 kg\u002Fm²\n5. Frailty: mFI ≥ 0.27\n6. Signed informed consent\n\nExclusion Criteria:\n\n1. Patients undergoing emergency surgery\n2. Patients with language disorders or severe hearing or vision impairment that prevent communication\n3. Patients with a history of neurological and psychiatric disorders, including Alzheimer's disease (AD), other types of dementia, stroke, and psychosis\n4. Patients with long-term use of psychotropic medications (such as clozapine, risperidone, olanzapine, haloperidol, and chlorpromazine)\n5. Patients who have undergone cardiac surgery or craniocerebral surgery within the past year\n6. Patients who have participated in other relevant clinical trials within the past 3 months\n7. Patients with preoperative cognitive impairment (Telephone Interview for Cognitive Status-modified (TICS-m) score ≤ 27), as determined via the TICS-M test\n8. Each patient can be included only once, regardless of whether the reason for the second surgery is related to the primary cause\n9. Let me know if you need this in a different bullet style (e.g., asterisks) or with indentation adjustments.",{"count":218,"type":22},174,[82],"Postoperative delirium (POD) is a common acute and transient form of brain dysfunction in elderly patients following surgery that can lead to serious adverse clinical outcomes and even death. Although existing studies have preliminarily investigated the effects of opioid-free anaesthesia (OFA) on POD, high-quality evidence on these effects for elderly patients undergoing gastrointestinal surgery remains limited. This study aims to investigate the effects of OFA on the development of POD in elderly patients following gastrointestinal surgery. This single-centre, prospective, randomized controlled trial will be conducted at the First Affiliated Hospital of Shandong First Medical University, China. A total of 654 patients aged 65 years or older who are scheduled for elective gastrointestinal surgery will be randomly allocated to receive either opioid-free anaesthesia (OFA; dexmedetomidine, esmolol, and esketamine) or conventional opioid-based anaesthesia (OBA). The primary outcome is the incidence of POD 7 days after surgery. The secondary outcomes are all-cause mortality within 30 days after surgery, intraoperative haemodynamic changes, the 15-item quality of recovery (QoR-15) scores at 24 h, 48 h, and 72 h after surgery, complications during postoperative hospitalization, pain numerical rating scale (NRS) score at 72 h after surgery, incidence of nausea and vomiting at 72 h after surgery, morphine milligram equivalent for analgesics at 72 h after surgery, duration of anaesthesia (from induction to discontinuation), duration of surgery (from skin incision to the last suture), duration of post-anaesthesia care unit (PACU) stay, and length of hospital stay. The results of this study may shed light on the effects of OFA on POD in elderly patients undergoing gastrointestinal surgery. The study is designed on the basis of the following key hypothesis: the use of opioid drugs for anaesthesia may increase the risk of POD through mechanisms such as blood-brain barrier destruction, neuroinflammatory responses, and central nervous system depression. Through the single-centre and prospective design of this randomized controlled trial, this study will directly analyse differences in the effects of OFA and conventional OBA on the incidence of POD, haemodynamic stability and long-term cognitive function in elderly patients.",[222,223],"Postoperative Delirium","Gastrointestinal Tumors",[225,226,227,228],"elderly patients","opioid-free anaesthesia","postoperative delirium","gastrointestinal surgery","2026-05-16",{"date":231,"type":37},"2026-05-22",{"date":233,"type":22},"2026-05-01",{"date":235,"type":22},"2028-06-30",{"name":43,"class":44},{"id":238,"slug":239,"hasResults":12,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":4,"eligibilityCriteria":243,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":244,"targetDuration":4,"studyType":118,"phases":4,"briefSummary":246,"conditions":247,"keywords":248,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":256,"locationsCount":257},"100633752","real-world-effectiveness-of-benralizumab-in-allergic-bronchopulmonary-aspergillosis-100633752","NCT07530770","Real-World Effectiveness of Benralizumab in Allergic Bronchopulmonary Aspergillosis","Effectiveness and Safety of Benralizumab in Allergic Bronchopulmonary Aspergillosis (ABPA): a Prospective Study of Real-world Experience","Inclusion Criteria:\n\n* Female and Male patients aged 18-75 years inclusively at the time of Visit 1 with a physician diagnosis of Allergic Bronchopulmonary Aspergillosis has met the ISHAM Working Group Diagnostic Criteria for ABPA:\n\nPredisposing condition: Bronchial asthma Obligatory criteria (both should be present)\n\nType I aspergillus skin test positive (immediate cutaneous hypersensitivity Aspergillus antigen) or elevated IgE level against Aspergillus fumigatus (Af) Aspergillus niger or Aspergillus flavus may be eligible provided antigen-specific IgE and IgG measurements are available for use.\n\nElevated total IgE levels (\\>1,000IU\u002FmL)\\* Other criteria (at least two of three)\n\nPresence of precipitating or IgG antibodies against Af in serum Radiographic pulmonary opacities consistent with ABPA Total eosinophil count \\>500 cells\u002FuL in steroid naïve patients (may be historical)\n\n(if the patient meets all other criteria, an IgE value \\\u003C1,000 IU\u002FmL may be acceptable) Severe chronic asthma (for at least 12 months) requiring treatment with high dose ICS plus asthma controller prior to Visit 1\n\nOther acceptable asthma controllers include long acting bronchodilators (e.g. a long acting beta-agonist (LABA) or long-acting muscarinic antagonists (LAMA)), a leukotriene inhibitor, theophylline preparations and\u002For maintenance OCS (daily or every other day OCS requirement in order to maintain asthma control Documented current treatment with high daily doses of ICS ( \\>500ug of FP equivalent) plus at least one other asthma controller for at least 3 months prior to Visit 1\n\nFor ICS\u002FLABA combination preparation, highest-strength maintenance doses approved in the U.S. will meet this criterion If the ICS and the other asthma controller therapies are given by separate inhalers, then the patient must be on a high daily ICS dose for 3 months prior to entering the study.\n\nHistory of at least 2 asthma exacerbations while on ICS plus another asthma controller (see inclusion criterion 2 for examples) that required treatment with systemic corticosteroids (IM, IV, or oral) in the 12 months prior to Visit 1. For patients receiving oral corticosteroids as a maintenance therapy, an exacerbation is defined as a temporary increase of their maintenance dose for a minimum of 3 days.\n\nWeight \\> 40kg\n\nExclusion Criteria:\n\n* Clinical important pulmonary disease other than asthma with allergic bronchopulmonary aspergillosis (ie. chronic obstructive pulmonary disease (COPD), cystic fibrosis, sarcoid, and pulmonary fibrosis) History of anaphylaxis to any biologic therapy Known history of allergy or hypersensitivity reaction to benralizumab or any of its components Current smokers or former smokers with a smoking history of \\> 10 pack years. A former smoker is defined as a patient who quit smoking at least 6 months prior to Visit 1.\n\nCurrently pregnant, breastfeeding, or lactating women Concurrent enrollment in another interventional or post-authorization safety study, unless it is observational.",{"count":245,"type":22},20,"An open-label study will evaluate effects of Benralizumab in the treatment of severe asthma in patients with allergic bronchopulmonary aspergillosis",[28,29,30],[30,249],"Benralizumab","2026-04-16",{"date":252,"type":37},"2026-04-21",{"date":254,"type":37},"2025-09-01",{"date":103,"type":22},{"name":43,"class":44},2,{"id":259,"slug":260,"hasResults":12,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":4,"eligibilityCriteria":264,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":265,"targetDuration":267,"studyType":118,"phases":4,"briefSummary":268,"conditions":269,"keywords":273,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":275,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":280,"locationsCount":45},"100620828","a-cohort-study-of-the-efficacy-and-safety-of-biologics-in-patients-with-abpa-100620828","NCT07362693","A Cohort Study of the Efficacy and Safety of Biologics in Patients With ABPA","A Prospective, Multicenter, Observational Cohort Study on the Efficacy and Safety of Biological Agents in Patients With Allergic Bronchopulmonary Aspergillosis","Inclusion Criteria:\n\n1. Meet the diagnostic criteria of allergic bronchopulmonary aspergillosis, according to the ISHAM guidelines for the diagnosis and treatment of allergic bronchopulmonary aspergillosis (2024 revision).\n2. The underlying disease was bronchial asthma, and it was severe bronchial asthma.\n3. Have had an acute asthma attack in the past year. Acute exacerbation of asthma is defined as the sudden onset of wheezing, shortness of breath, cough, chest tightness and other symptoms beyond the definition of uncontrolled asthma, or the aggravation of the original symptoms, and is characterized by decreased expiratory flow, often induced by exposure to allergens, irritants or respiratory tract infection.\n4. Blood eosinophil count ≥150 cells \u002FμL.\n5. Age ≥ 18 years old.\n\nExclusion Criteria:\n\n1. The underlying diseases were chronic obstructive pulmonary disease and bronchiectasis;\n2. Known allergic history to biological agents;\n3. Human immunodeficiency virus infection, active pulmonary tuberculosis or pulmonary malignant tumor;\n4. Complicated with other diseases requiring long-term systemic use of glucocorticoids or immunosuppressants (such as autoimmune diseases);\n5. Pregnant or lactating women;\n6. Currently participating in other interventional clinical research;\n7. Any other conditions considered by the investigator to preclude participation in the study (e.g., nonadherence, predicted survival \\\u003C1 year, or severe mental illness that prevented cooperation).",{"count":266,"type":22},50,"2 Years","To evaluate the efficacy and safety of biological agents in patients with allergic bronchopulmonary aspergillosis.",[30,270,121,271,28,272],"Biologics","Cohort Study","Efficacy and Safety",[274,28,270],"abpa",{"date":276,"type":37},"2026-04-17",{"date":278,"type":37},"2025-01-31",{"date":133,"type":22},{"name":43,"class":44},{"id":282,"slug":283,"hasResults":12,"nctId":284,"briefTitle":285,"officialTitle":286,"acronym":4,"eligibilityCriteria":287,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":288,"targetDuration":4,"studyType":23,"phases":290,"briefSummary":291,"conditions":292,"keywords":297,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":304,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":310,"locationsCount":45},"100580479","mepilex-lite-dressings-for-the-treatment-of-acute-radiation-dermatitis-of-anal-canal-skin-100580479","NCT06837831","Mepilex Lite Dressings for the Treatment of Acute Radiation Dermatitis of Anal Canal Skin","Clinical Efficacy of Mepilex Lite Dressings Combined With Indomethacin Suppositories in the Treatment of Acute Radiation Dermatitis Caused by Rectal Cancer Radiotherapy: a Randomized Controlled Trial","Inclusion criteria\n\n1. Confirmed rectal cancer by histopathological diagnosis;\n2. Individuals with clear indications for radiotherapy;\n3. Individuals who receive radiation therapy for the first time and develop grade 2 or higher acute radiation dermatitis after receiving radiation therapy;\n4. Age ≥ 18 years old;\n5. Those who voluntarily participate in this study and sign the informed consent form.\n\nExclusion criteria\n\n1. Individuals with allergic constitution and allergies to the drugs and materials used in this study;\n2. Those who withdraw or interrupt radiotherapy midway;\n3. Individuals with mental illness, emotional instability, or inability to express their own feelings;\n4. Individuals with various comorbidities such as serious cardiovascular and cerebrovascular diseases, digestive system diseases, hematological diseases, and infectious diseases;\n5. Physical condition score (Eastern Cooperative Oncology Group, ECOG) \\>3 points;\n6. Individuals suffering from anal fissures and other diseases that cause skin damage to the anal canal;\n7. Individuals with an artificial anus.",{"count":289,"type":22},274,[25],"Background: According to GLOBOCAN 2022 statistics, colorectal cancer has become the third most common cancer disease worldwide, and also the second leading cause of death. The incidence rate of rectal cancer is particularly prominent. Radiotherapy is one of the important methods for comprehensive treatment of rectal cancer, but the radiation damage caused by radiotherapy cannot be ignored. During radiotherapy for rectal cancer, the skin of the anal canal will be damaged by radiation, resulting in acute radiation dermatitis, which is characterized by redness, pain, and ulcers. The main symptom of patients is anal pain. As the radiation dose accumulates, the skin damage to the anal canal becomes increasingly severe, and the patient's anal pain becomes more severe, which seriously affects the patient's quality of life. Mepilex Lite Dressings can absorb the exudate, keep it moist, promote the healing of radioactive dermatitis, and relieve pain. However, when inserting into the anal canal, the patient reported significant pain that was difficult to tolerate. Therefore, indomethacin suppositories were administered rectally before inserting the dressing, which has been proven to have a reliable analgesic effect by research. In summary, the main objective of this study is to determine the effectiveness of Mepilex Lite Dressings combined with indomethacin suppositories in the treatment of acute radiation dermatitis of anal canal skin in patients with rectal cancer undergoing radiotherapy.\n\nMethod: The research plan will be a prospective randomized controlled trial. Participants were randomly divided into an experimental group (n=137) and a control group (n=137) using a simple randomization method. The control group received indomethacin suppositories and routine nursing measures, while the experimental group received the same treatment as the control group and received insertion of Meipile Lite Dressing into the anal canal. The primary outcome measure was the effective rate of treatment for acute radiation dermatitis of the anal canal skin on the 14th day after intervention, and the secondary outcome measure was the effective rate of treatment for acute radiation dermatitis of the anal canal skin on the 7th and 21st days after intervention. At the same time, a questionnaire survey was conducted using the Digital Pain Assessment Scale, Anxiety and Depression Scale, Pittsburgh Sleep Quality Index, and Skin Disease Patient Quality of Life Scale at baseline and on the 7th, 14th, and 21st days after intervention.",[293,294,295,296],"Rectal Cancer, Radiotherapy","Anal Pain","Acute Radiation Dermatitis","Anal Canal",[298,299,300,301,302,296],"Rectal cancer","mepilex lite dressings","indomethacin suppository","anal pain","Acute radiation dermatitis","2026-04-06",{"date":305,"type":37},"2026-04-13",{"date":307,"type":37},"2026-02-01",{"date":309,"type":22},"2027-07-31",{"name":43,"class":44},{"id":312,"slug":313,"hasResults":12,"nctId":314,"briefTitle":315,"officialTitle":316,"acronym":317,"eligibilityCriteria":318,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":319,"targetDuration":4,"studyType":118,"phases":4,"briefSummary":321,"conditions":322,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":326,"lastUpdatePostDateStruct":327,"startDateStruct":329,"completionDateStruct":331,"leadSponsor":333,"locationsCount":4},"100629149","preoperative-fish-oil-pn-and-prognosis-after-constipation-surgery-100629149","NCT07470892","Preoperative Fish Oil PN and Prognosis After Constipation Surgery","Impact of Preoperative Fish Oil-Containing Parenteral Nutrition on Prognosis in Patients Undergoing Surgery for Constipation: A Prospective, Multicenter, Real-World Study","FOCP","Inclusion Criteria:\n\n1. Age 18 to 75 years.\n2. Meets diagnostic criteria for slow-transit constipation (STC) or megacolon and is scheduled for elective colon surgery.\n3. Nutritional Risk Screening 2002 (NRS2002) score \\>=3.\n4. Receives fish oil-containing parenteral nutrition (PN) for \\>=3 days preoperatively or initiates PN for the first time postoperatively (according to the study cohort definition).\n5. Voluntarily participates in the study and provides signed informed consent.\n\nExclusion Criteria:\n\n1. Mental disorders or other conditions that prevent cooperation with treatment or follow-up.\n2. Pregnant or breastfeeding women, women planning pregnancy \u002F in a pre-pregnancy state, or women with a clear intention to become pregnant during the perioperative period or follow-up.\n3. Contraindications to surgery or parenteral nutrition.\n4. Concurrent enrollment in another study.\n5. No baseline data available before initiation of nutritional support treatment.\n6. Any other condition judged by the investigator to make the participant unsuitable for this study.",{"count":320,"type":22},306,"This is a prospective, multicenter, real-world observational study to evaluate the impact of perioperative parenteral nutrition (PN) with fish oil-containing lipid emulsion on outcomes in adult patients with constipation undergoing elective colon surgery.\n\nThe study will compare two clinical nutrition strategies: (1) PN with fish oil-containing lipid emulsion started before surgery and continued after surgery, and (2) PN with fish oil-containing lipid emulsion started only after surgery. Eligible participants are adults (18-75 years) with slow-transit constipation (STC) or megacolon who are scheduled for elective colon surgery and have nutritional risk (NRS2002 score \\>=3).\n\nThe primary objective is to compare the incidence of postoperative complications between these two PN timing strategies. Secondary objectives include comparison of perioperative nutritional status, postoperative inflammatory status, prognosis, and safety outcomes.\n\nThis study will collect and analyze clinical data, laboratory indicators, perioperative recovery outcomes, follow-up assessments, and safety information in routine clinical practice. Outcomes include postoperative complication rates, changes in nutritional and inflammatory markers, bowel function recovery, length of hospital stay, constipation-related symptoms, quality of life, and adverse events. No experimental intervention will be assigned as part of this observational study.\n\nThe planned sample size is 306 participants. The findings may help optimize perioperative nutritional support strategies for patients with constipation undergoing surgery.",[323,324,325],"Constipation","Slow Transit Constipation","Megacolon","2026-03-10",{"date":328,"type":37},"2026-03-13",{"date":330,"type":22},"2026-03",{"date":332,"type":22},"2029-09",{"name":43,"class":44},{"id":335,"slug":336,"hasResults":12,"nctId":337,"briefTitle":338,"officialTitle":339,"acronym":4,"eligibilityCriteria":340,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":341,"targetDuration":4,"studyType":118,"phases":4,"briefSummary":343,"conditions":344,"keywords":349,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":353,"startDateStruct":355,"completionDateStruct":357,"leadSponsor":358,"locationsCount":45},"100620826","a-study-of-the-efficacy-and-safety-of-bronchoscopic-airway-clearance-and-amphotericin-b-spraying-in-patients-with-abpa-100620826","NCT07362667","A Study of the Efficacy and Safety of Bronchoscopic Airway Clearance and Amphotericin B Spraying in Patients With ABPA","A Prospective, Multicenter, Observational Cohort Study on the Efficacy and Safety of Bronchoscopic Airway Clearance and Amphotericin B Spraying in Patients With Allergic Bronchopulmonary Aspergillosis","Inclusion Criteria:\n\n1. Meet the diagnostic criteria of allergic bronchopulmonary aspergillosis, according to the ISHAM guidelines for the diagnosis and treatment of allergic bronchopulmonary aspergillosis (2024 revision), and the presence of mucus plugs or hyperattenuated mucus confirmed by chest high-resolution CT (HRCT).\n2. Active disease: Newly diagnosed allergic bronchopulmonary aspergillosis or an acute exacerbation after discontinuation of treatment (defined as a \\> 14 day history of clinical worsening or radiographic progression of allergic bronchopulmonary aspergillosis and a ≥50% increase in total serum IgE from the last recorded value during the stable phase, excluding other causes of the acute exacerbation) in patients with previously diagnosed allergic bronchopulmonary aspergillosis.\n3. Age ≥ 18 years old.\n\nExclusion Criteria:\n\n1. Allergic bronchopulmonary aspergillosis - serotype (i.e., meets the diagnostic criteria for allergic bronchopulmonary aspergillosis, but chest CT shows no obvious abnormality);\n2. Patients with absolute or relative contraindications to electronic bronchoscopy;\n3. Known history of allergy to amphotericin B or any of its excipients;\n4. Patients with bronchiectasis caused by human immunodeficiency virus infection, active tuberculosis, pulmonary malignant tumor or other non-allergic bronchopulmonary aspergillosis;\n5. Combined with other diseases requiring long-term systemic use of glucocorticoids or immunosuppressants (such as autoimmune diseases);\n6. Patients with previous or current smoking history;\n7. Pregnant or lactating women;\n8. Currently participating in other interventional clinical research;\n9. Any other conditions considered by the investigator to preclude participation in the study (e.g., nonadherence, predicted survival \\\u003C1 year, or severe mental illness that prevented cooperation).",{"count":342,"type":22},44,"To evaluate the efficacy and safety of bronchoscopic airway clearance and amphotericin B spraying in the treatment of allergic bronchopulmonary aspergillosis",[30,28,121,345,346,347,348],"Airway Clearance","Mucus Plug","Amphotericin B","Bronchoscope",[28,30,347,350,345,351],"bronchoscope","mucus plug","2026-01-15",{"date":354,"type":37},"2026-01-23",{"date":356,"type":37},"2026-01-10",{"date":133,"type":22},{"name":43,"class":44},{"id":360,"slug":361,"hasResults":12,"nctId":362,"briefTitle":363,"officialTitle":363,"acronym":364,"eligibilityCriteria":365,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":366,"targetDuration":368,"studyType":118,"phases":4,"briefSummary":369,"conditions":370,"keywords":372,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":376,"lastUpdatePostDateStruct":377,"startDateStruct":378,"completionDateStruct":380,"leadSponsor":381,"locationsCount":4},"100612990","clinical-comprehensive-evaluation-of-neuroprotective-drugs-for-acute-ischemic-stroke-100612990","NCT07260760","Clinical Comprehensive Evaluation of Neuroprotective Drugs for Acute Ischemic Stroke","Ischemic strok","Inclusion Criteria:\n\n* 1: Age≥18\n\n  2: Acute ischemic stroke in the anterior circulation occurring within 48 hours\n\n  3: Baseline NIHSS score of 1-15 points (mild stroke: baseline NIHSS score of 1-5 points; moderate stroke: baseline NIHSS score of 6-15 points)\n\n  4: Pre-onset mRS score≤1\n\n  5: Use of Edaravone (injection or tablets)\n\n  6: Exclude intracranial hemorrhage\n\n  7: Sign the informed consent form\n\nExclusion Criteria:\n\n* 1: A head CT or MRI scan indicates the presence of intracranial hemorrhagic disease\n\n  2: Patients with cerebral embolism or suspected cerebral embolism who also have severe atrioventricular block, atrial fibrillation, myocardial infarction, valvular heart disease, infective endocarditis, or a heart rate below 50 beats per minute\n\n  3: Abnormal liver function (ALT or AST transaminase levels exceeding the upper limit of normal), abnormal kidney function (creatinine levels exceeding the upper limit of normal), or individuals with other severe systemic diseases, etc\n\n  4: Allergy to the test drug",{"count":367,"type":22},600,"90 Days","This study conducted a comprehensive evaluation of commonly used neuroprotective agents in acute ischemic stroke, assessing their real-world value across six dimensions: safety, efficacy, cost-effectiveness, innovativeness, appropriateness, and accessibility. Employing a prospective observational design, it primarily investigates the association of edaravone and dexrazoxane with clinical outcomes in patients with mild-to-moderate stroke, with subgroup analyses performed according to Trial of Org 10172 in Acute Stroke Treatment （TOAST ）classification.",[371],"Acute Ischemic Stroke",[373,374,375],"Acute ischemic stroke","Neuroprotective drugs","Real-world studies","2026-01-14",{"date":352,"type":37},{"date":379,"type":22},"2026-01-20",{"date":133,"type":22},{"name":43,"class":44},{"id":383,"slug":384,"hasResults":12,"nctId":385,"briefTitle":386,"officialTitle":387,"acronym":388,"eligibilityCriteria":389,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":390,"enrollmentInfo":391,"targetDuration":4,"studyType":23,"phases":393,"briefSummary":394,"conditions":395,"keywords":399,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":402,"lastUpdatePostDateStruct":403,"startDateStruct":405,"completionDateStruct":407,"leadSponsor":409,"locationsCount":45},"100613842","phase-4-nalbuphine-timing-effects-on-hemodynamics-and-analgesia-in-elderly-patients-100613842","NCT07271849","Nalbuphine Timing Effects on Hemodynamics and Analgesia in Elderly Patients","Effects of Different Administration Timings of Nalbuphine on Hemodynamics and Postoperative Analgesia in Elderly Patients Undergoing Total Knee Arthroplasty","TKA","Inclusion Criteria:\n\n* All study participants voluntarily enrolled in the trial and provided written informed consent after being fully informed of the trial's purpose and significance\n* Participants underwent unilateral total knee arthroplasty under general anesthesia\n* Elderly participants (age ≥ 65 years), regardless of gender\n* Body mass index (BMI) ranging from 18 kg\u002Fm² to 30 kg\u002Fm²\n* Absence of psychiatric disorders, normal consciousness, and ability to communicate effectively\n* American Society of Anesthesiologists (ASA) physical status classification I-III;\n* No contraindications to the study medications\n\nExclusion Criteria:\n\n* Study participants with uncontrolled or untreated hypertension (resting systolic\u002Fdiastolic blood pressure \\>180\u002F100 mmHg)\n* Individuals with severe respiratory diseases\n* Subjects with abnormal liver or renal function (ALT and\u002For AST \\>2.5 times the upper limit of normal, total bilirubin \\>1.5 times the upper limit of normal, serum creatinine \\>1.5 times the upper limit of normal)\n* Individuals with a history of drug abuse, illicit drug use, or alcohol abuse, where alcohol abuse is defined as an average daily alcohol intake exceeding 2 units (1 unit = 360 mL of beer, 45 mL of 40% alcohol by volume spirits, or 150 mL of wine)","90 Years",{"count":392,"type":22},162,[57],"In total knee arthroplasty (TKA), the use of a tourniquet and controlled hypotension is common. However, ischemia-reperfusion injury induced by the tourniquet and inappropriate controlled hypotension can lead to cardiac and cerebral damage in patients. Consequently, maintaining hemodynamic stability, ensuring adequate cerebral perfusion, and achieving controlled blood pressure during the perioperative period are critical factors influencing patient outcomes. Postoperatively, patients typically experience moderate to severe pain. Severe postoperative pain can result in prolonged hospital stays, increased readmission rates, elevated opioid consumption, and associated nausea and vomiting. Therefore, exploring effective multimodal postoperative pain management strategies is essential. Nalbuphine, an opioid analgesic acting as a full kappa-receptor agonist and a partial mu-receptor antagonist, is considered to provide analgesic efficacy equivalent to morphine while potentially offering advantages in maintaining hemodynamic stability. This study aims to investigate the effects of administering equivalent doses of nalbuphine at different perioperative time points on analgesia and hemodynamics in elderly patients undergoing knee arthroplasty.",[396,397,398],"Postoperative Pain, Acute","Hemodynamics","Total Knee Arthroplasty (TKA)",[398,400,401,397],"Postoperative Pain","Nalbuphine","2025-12-06",{"date":404,"type":37},"2025-12-09",{"date":406,"type":37},"2025-10-28",{"date":408,"type":22},"2026-10-31",{"name":43,"class":44},{"id":411,"slug":412,"hasResults":12,"nctId":413,"briefTitle":414,"officialTitle":415,"acronym":4,"eligibilityCriteria":416,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":53,"enrollmentInfo":417,"targetDuration":4,"studyType":23,"phases":419,"briefSummary":420,"conditions":421,"keywords":4,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":424,"lastUpdatePostDateStruct":425,"startDateStruct":427,"completionDateStruct":428,"leadSponsor":430,"locationsCount":45},"100596439","phase-1-remimazolam-infusion-in-kidney-transplant-patients-a-multicenter-study-100596439","NCT07045467","Remimazolam Infusion in Kidney Transplant Patients: A Multicenter Study","Pharmacokinetics and Pharmacodynamics of Continuous Infusion of Remimazolam in Kidney Transplant Recipients: A Multicenter Interventional Study","Inclusion Criteria Signed informed consent\n\nAge ≥18 years and \\\u003C65 years\n\nChronic renal failure scheduled for renal transplantation\n\nBody mass index (BMI) 18-30 kg\u002Fm² (inclusive)\n\nWeight ≥50 kg (males) or ≥45 kg (females)\n\nASA physical status classification III or IV\n\nExclusion Criteria Hepatic, psychiatric, or neurological disorders\n\nCoagulopathy\n\nHeart failure\n\nRespiratory failure\n\nLong-term sedative or antidepressant use\n\nPregnancy or lactation\n\nInability to communicate or cooperate\n\nParticipation in other drug\u002Fdevice trials within 3 months prior\n\nPositive hepatitis B surface antigen (HBsAg)\n\nPositive hepatitis C antibody (HCV-Ab)\n\nPositive HIV antibody\n\nPositive syphilis antibody\n\nUse of hepatic enzyme inhibitors\u002Finducers within 30 days prior (per Appendix 1)\n\nKnown hypersensitivity to ≥2 substances\n\nAlcohol consumption \\>14 units\u002Fweek within 6 months prior\\*\n\nDrug abuse history within 3 months prior\n\nMajor infection\u002Ftrauma within 1 month prior\n\nGastrointestinal surgery affecting drug absorption within 1 month prior\n\nVaccination within 1 month prior or planned during study\n\nBlood loss\u002Fdonation \\>400 mL within 3 months prior\n\nBlood transfusion within 1 month prior\n\nINR \\>1.5, PT \\>ULN+4 seconds, or APTT \\>15×ULN\n\nSignificant bleeding history within 3 months prior\n\nCurrent anticoagulant therapy\n\nAny condition deemed unsuitable by investigator",{"count":418,"type":22},30,[82],"The goal of this clinical trial is to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of remimazolam (CNS 70754) in healthy adult participants. The main questions it aims to answer are:\n\nWhat are the key pharmacokinetic parameters of remimazolam, including peak concentration (Cmax), time to peak concentration (Tmax), area under the curve (AUC), and elimination half-life (T1\u002F2)? What is the effect of remimazolam on consciousness, as measured by the MOAA\u002FS scale and Narcotrend monitoring during anesthesia? Researchers will compare the pharmacokinetic and pharmacodynamic effects of remimazolam to see if the drug provides consistent and predictable sedation without significant adverse effects.\n\nParticipants will:\n\nReceive continuous Infusion of Remimazolam. Have blood samples taken at various time points to measure plasma concentrations and calculate PK parameters.\n\nBe monitored for consciousness and sedation levels using the MOAA\u002FS scale and Narcotrend.\n\nUndergo safety assessments, including laboratory tests, vital signs monitoring, and physical examinations throughout the study.\n\nThis study will help determine the drug's behavior in the body and its impact on sedation, providing valuable information for its future clinical use in anesthesia and other medical applications.\n\nLast updated on December 22, 2024",[422,423],"Chronic Kidney Diseases","Renal Transplantation","2025-09-25",{"date":426,"type":37},"2025-10-01",{"date":159,"type":37},{"date":429,"type":22},"2027-06-01",{"name":43,"class":44},{"id":432,"slug":433,"hasResults":12,"nctId":434,"briefTitle":435,"officialTitle":436,"acronym":4,"eligibilityCriteria":437,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":438,"enrollmentInfo":439,"targetDuration":4,"studyType":23,"phases":441,"briefSummary":443,"conditions":444,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":449,"startDateStruct":451,"completionDateStruct":452,"leadSponsor":453,"locationsCount":45},"100608037","phase-1-tas-102-plus-radiotherapy-in-elderly-escc-100608037","NCT07196345","TAS-102 Plus Radiotherapy in Elderly ESCC","Efficacy and Safety of Trifluridine\u002FTipiracil Combined With Radiotherapy in Elderly Patients With Locally Advanced Esophageal Cancer","Inclusion Criteria:\n\n* Patients must have newly confirmed histologically or cytologically diagnosed esophageal squamous cell carcinoma.\n* Age between 65 and 85 years.\n* Esophageal cancer staged as IIB to IVB according to the 8th edition AJCC staging system (including IVB with supraclavicular or celiac lymph node metastasis, but excluding IVB with other distant metastases).\n* ECOG performance status of 0 or 1.\n* No history of esophageal perforation, active esophageal bleeding, or significant invasion of the trachea or major thoracic blood vessels.\n* No prior anticancer therapy such as radiotherapy or chemotherapy. Adequate bone marrow function: hemoglobin ≥9 g\u002FdL, white blood cells ≥3.0×10⁹\u002FL, neutrophils ≥1.5×10⁹\u002FL, platelets ≥100×10⁹\u002FL.\n* Adequate liver and kidney function: serum creatinine (Scr) ≤1.5×ULN, total bilirubin ≤1.5×ULN, ALT and AST ≤2.5×ULN.\n* No history of interstitial lung disease.\n* Forced expiratory volume (FEV1) ≥0.8 liters.\n* Signed informed consent form before study initiation.\n\nExclusion Criteria:\n\n* Patients with hematogenous metastasis or distant lymph node metastasis (except supraclavicular or celiac lymph node metastasis), multiple esophageal cancer lesions, or malignant pleural\u002Fpericardial effusion.\n* History of radiotherapy, chemotherapy, or surgery targeting the primary tumor or lymph nodes.\n* Tracheoesophageal fistula, invasion of the trachea or main bronchi by the primary tumor, deep esophageal ulcer, or hematemesis.\n* Severe comorbidities such as active infection, cardiovascular disease, or pulmonary disease.\n* History of other malignancies except adequately treated non-melanoma skin cancer.\n* Participation in another clinical trial within the past 30 days.\n* Any other condition deemed by the investigator to preclude participation in the study.","85 Years",{"count":440,"type":22},45,[82,442],"PHASE2","This study is a single-arm, multicenter clinical trial evaluating the efficacy and safety of radiotherapy combined with TAS-102 monotherapy in elderly patients with locally advanced esophageal cancer.\n\nTreatment Phase: The treatment phase is divided into a Phase I stage and a Phase II stage. The Phase I stage aims to explore the maximum tolerated dose (MTD) of TAS-102 in elderly esophageal cancer patients. A total of 9 subjects were enrolled, and the dose was escalated from 30 mg\u002Fm² in 5 mg\u002Fm² increments up to 40 mg\u002Fm². The MTD was defined as the highest drug dose at which no dose-limiting toxicity (DLT) was observed in more than 40% of treated patients during the first two weeks of combined radiotherapy and TAS-102 administration. The Phase II stage aims to investigate the efficacy of radiotherapy combined with TAS-102 at the MTD in elderly esophageal cancer patients, with 36 subjects enrolled.\n\nConsolidation Phase: Following the treatment phase, subjects had a 3-4 week rest period. This was followed by consolidation therapy with TAS-102 monotherapy at a dose of 35 mg\u002Fm², administered twice daily on days 1-5 of a 28-day cycle for two cycles.\n\nSubsequently, patients entered the efficacy and safety follow-up phase until the study endpoints were reached or after a full 2-year follow-up period.",[445,446,447],"ESCC","TAS 102","Radiotherapy","2025-09-21",{"date":450,"type":37},"2025-09-29",{"date":424,"type":22},{"date":133,"type":22},{"name":43,"class":44},{"id":455,"slug":456,"hasResults":12,"nctId":457,"briefTitle":458,"officialTitle":459,"acronym":4,"eligibilityCriteria":460,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":170,"enrollmentInfo":461,"targetDuration":4,"studyType":23,"phases":463,"briefSummary":464,"conditions":465,"keywords":468,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":473,"lastUpdatePostDateStruct":474,"startDateStruct":476,"completionDateStruct":478,"leadSponsor":479,"locationsCount":4},"100525917","phase-1-the-relationship-between-nlr-and-ponv-and-espb-100525917","NCT06127966","The Relationship Between NLR and PONV and ESPB","The Relationship Between the Preoperative Neutrophil-to-lymphocyte Ratio (NLR) and Postoperative Nausea and Vomiting (PONV) in Lumbar Spine Surgery Patients, as Well as the Impact of Erector Spinae Plane Block on NLR and PONV","Inclusion Criteria:\n\n1. Patients undergoing elective posterior lumbar spine surgery in a prone position under general anesthesia.\n2. ASA classification grades I to II.\n3. Age between 18 and 80 years old.\n4. Signed the informed consent for this study.\n\nExclusion Criteria:\n\n1. Preoperative blood transfusion.\n2. Uncontrolled systemic diseases.\n3. Patients with known uncontrolled systemic inflammatory diseases (e.g., rheumatoid arthritis, lupus, or active infections).\n4. Gastrointestinal system disorders.\n5. History of antiemetic and anticholinergic drug use.\n6. History of adverse reactions related to surgery, deformity correction surgeries, defined as procedures involving instrumentation across three or more levels or aimed at correcting scoliosis or kyphosis.\n7. Severe spinal deformities.\n8. Infection at the puncture site.\n9. Coagulation disorders.\n10. Long-term use of sedatives and analgesic drugs before surgery.\n11. Patients with mental illness or communication barriers.\n12. Allergic to ropivacaine.\n13. Participants involved in other clinical studies within the past 3 months.\n14. History of previous lumbar surgeries.\n15. Subjective unwillingness to participate in this study.",{"count":462,"type":22},220,[82],"This study aims to investigate whether preoperative NLR (Neutrophil-to-Lymphocyte Ratio) serves as a biomarker for PONV (Postoperative Nausea and Vomiting). It also examines the impact of erector spinae plane block on NLR and PONV. Furthermore, the research explores the effect of erector spinae plane block on postoperative pain relief in spinal surgery and its influence on the usage of opioid medications.",[466,467],"Erector Spinae Plane Block","Neutrophil to Lymphocyte Ratio",[467,469,470,471,472],"Postoperative Nausea and Vomiting","erector spinae plane block","Postoperative analgesia","lumbosacral spine surgery","2025-07-24",{"date":475,"type":37},"2025-07-29",{"date":477,"type":22},"2025-08-01",{"date":39,"type":22},{"name":43,"class":44},{"id":481,"slug":482,"hasResults":12,"nctId":483,"briefTitle":484,"officialTitle":485,"acronym":486,"eligibilityCriteria":487,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":170,"enrollmentInfo":488,"targetDuration":4,"studyType":23,"phases":490,"briefSummary":491,"conditions":492,"keywords":494,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":500,"lastUpdatePostDateStruct":501,"startDateStruct":502,"completionDateStruct":504,"leadSponsor":505,"locationsCount":45},"100578403","sedation-of-remazolam-combined-with-afentanil-in-non-intubated-thoracoscopic-pulmonary-surgery-100578403","NCT06810843","Sedation of Remazolam Combined With Afentanil in Non-intubated Thoracoscopic Pulmonary Surgery","Sedation of Remazolam in Combination With Afentanil in Non-intubated Thoracoscopic Pulmonary Surgery: a Single-blind, Randomized, Controlled Trial","R-A NITS","Inclusion Criteria:\n\n* American Society of Anesthesiologists ASA Level I to III;\n* 18 years-80 years old;\n* Non-intubated thoracoscopic lung surgery under deep sedation;\n* 18 kg\u002Fm2≤BMI≤30 kg\u002Fm2;\n* Voluntarily participate in the study and sign the informed consent.\n\nExclusion Criteria:\n\n* Pulmonary function tests showed moderate to severe ventilation or exchange disorders (FEV1\\\u003C 60% of the predicted value, carbon monoxide diffusion \\\u003C 60% of the predicted value);\n* Abnormal liver and kidney function (Child-Pugh grade liver function is grade B and grade C; Endogenous creatinine clearance ≤50mL\u002Fmin, serum creatinine \\>178µmol\u002FL or urea nitrogen \\>9mmol\u002FL by renal function test);\n* SpO2 \\\u003C 95% before operation;\n* History of recovery from abnormal surgical anesthesia;\n* History of thoracic surgery or history of tuberculosis or systemic infection within one month;\n* Severe cardiovascular and cerebrovascular diseases (patients with severe cardiovascular and cerebrovascular diseases:\n\nHigh risk of hypertension, untreated coronary heart disease, valvular heart disease, previous myocardial infarction, cerebral infarction, cerebral thrombus, cerebral hemorrhage);\n\n* Take monoamine oxidase inhibitors or antidepressants within 15 days;\n* Chronic pain from long-term use of analgesics or psychotropic drugs, alcoholism;\n* Known drug allergy;\n* Expected difficult airway;\n* Pregnant women or women giving birth;\n* Participation in other drug trials within three months or inability to communicate well with researchers",{"count":489,"type":22},390,[25],"Non-intubated Thoracoscopic surgery (NITS) is a newly emerging minimally invasive surgical technique in recent years . Compared with traditional intubation general anesthesia, it has the advantages of less trauma, faster recovery and fewer complications . This surgical method allows patients to perform under local anesthesia or regional block and moderate sedation, providing a physiologic ventilation method , reducing the intervention on the respiratory system and conducive to rapid postoperative recovery.\n\nThe importance of sedative drugs in non-intubated thoracoscopic surgery Successful implementation of non-intubated thoracoscopic surgery requires sound regional block, airway management, and rational use of intravenous sedation and analgesics . In addition, sedative drugs need to have less respiratory and circulatory inhibition and fewer side effects. Propofol, as the most commonly used sedative drug, has a high incidence of adverse reactions such as injection pain and respiratory and circulatory inhibition. A large number of meta-analyses and systematic reviews have compared the sedative effects of remazolam and propofol, proving that Remazolam, as a new sedative, has advantages such as short half-life, rapid onset, rapid recovery, and light respiratory and circulatory inhibition.Compared with traditional benzodiazepines, Remazolam has a shorter half-life, which is conducive to rapid postoperative wakeup and reduces the risk of discomfort and cognitive dysfunction in patients. In addition, remazolam has little influence on the respiratory system and is relatively stable on the circulatory system ，which is an ideal sedation option for non-intubated thoracoscopic surgery that retains spontaneous respiration. Afentanil mainly acts on μ opioid receptors , and its analgesic intensity is about 15 times that of morphine, which has the advantages of rapid onset, short duration of action, rapid recovery, high safety, and few adverse reactions . Afentanil has a short half-life , mild respiratory depression, low incidence of cough, postoperative nausea and vomiting . Remazolam combined with afentanil is widely used in various surgeries or examinations that preserve spontaneous breathing, such as gastroenteroscopy, ERCP, hysteroscopy, short-term plastic surgery and fiberbronchoscopy, and has shown the advantage of light respiratory circulation inhibition . We speculate that remazolam combined with afentanil may have certain advantages in non-intubated thoracoscopic surgery that retains spontaneous breathing. At present, the application of remazolam combined with afentanil in non-intubated thoracoscopic surgery is still lacking. The purpose of this study was to observe the safety and effectiveness of remazolam combined with afentanil in non-intubated thoracoscopic surgery, and to provide a better choice of sedation drugs for non-intubated thoracoscopic surgery.",[493],"Pulmonary Nodule Cm",[495,496,497,498,499],"Non-intubated thoracoscopic surgery","Tubleless VATS","Remazolam","alfentanyl","NITS","2025-07-20",{"date":473,"type":37},{"date":503,"type":22},"2025-12",{"date":41,"type":22},{"name":43,"class":44},{"id":507,"slug":508,"hasResults":12,"nctId":509,"briefTitle":510,"officialTitle":510,"acronym":4,"eligibilityCriteria":511,"healthyVolunteers":169,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":512,"targetDuration":4,"studyType":118,"phases":4,"briefSummary":514,"conditions":515,"keywords":4,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":516,"startDateStruct":518,"completionDateStruct":520,"leadSponsor":522,"locationsCount":45},"100596044","pathogenesis-and-inflammatory-phenotype-of-allergic-bronchopulmonary-aspergillosis-100596044","NCT07040332","Pathogenesis and Inflammatory Phenotype of Allergic Bronchopulmonary Aspergillosis","Inclusion Criteria:\n\n* Meets the diagnostic criteria for allergic bronchopulmonary aspergillosis.\n* Meets the diagnostic criteria for fungal-sensitized asthma.\n\nExclusion Criteria:\n\n* Human immunodeficiency virus infection.\n* Malignant tumor.\n* Blood system disease.\n* autoimmune system disease.\n* History of pulmonary tuberculosis.\n* Patients with a history of smoking or still smoking.\n* Invasive pulmonary fungal disease.\n* Contraindications electronic bronchoscopy",{"count":513,"type":22},140,"This study aims to reveal the immune and inflammatory regulatory molecular mechanisms related to the progression of allergic bronchopulmonary aspergillosis (ABPA), and to build a precision typing based on inflammation and identify the biomarkers of typing, and to explore the clinical outcomes of different inflammatory phenotypes.",[121],{"date":517,"type":37},"2025-07-04",{"date":519,"type":37},"2025-05-10",{"date":521,"type":22},"2029-01-31",{"name":43,"class":44},{"id":524,"slug":525,"hasResults":12,"nctId":526,"briefTitle":527,"officialTitle":528,"acronym":4,"eligibilityCriteria":529,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":170,"enrollmentInfo":530,"targetDuration":4,"studyType":23,"phases":532,"briefSummary":533,"conditions":534,"keywords":538,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":542,"lastUpdatePostDateStruct":543,"startDateStruct":545,"completionDateStruct":547,"leadSponsor":548,"locationsCount":45},"100593646","phase-2-ql1706-plus-bevacizumab-for-unresectable-or-metastatic-msi-hdmmr-crc-100593646","NCT07009145","QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H\u002FdMMR CRC","An Exploratory Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Bevacizumab for the Treatment of Unresectable or Metastatic MSI-H\u002FdMMR Colorectal Cancer","Inclusion Criteria:\n\n* Voluntarily signs the informed consent form.\n* Aged between 18 and 80 years (inclusive) at the time of consent; no gender restriction.\n* Histologically confirmed unresectable locally advanced or metastatic colorectal cancer.\n* At least one measurable target lesion according to RECIST v1.1.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* No prior immunotherapy for unresectable locally advanced or metastatic colorectal cancer.\n* If previously treated with standard neoadjuvant or adjuvant therapy, the interval from the last dose to the first study treatment must be ≥ 6 months.\n* Willing and able to provide tumor tissue and blood samples for MSI, RAS, BRAF, and PD-L1 testing.\n* Estimated life expectancy of ≥ 12 months.\n* Appropriate laboratory values must be met at screening.\n* Female participants must be non-lactating, and have a negative pregnancy test result prior to enrollment.\n* Participants of childbearing potential must agree to use effective contraception from the time of informed consent until at least 180 days after the last dose of study treatment.\n\nExclusion Criteria:\n\n* Known history of severe allergic reactions to iparomlimab and tuvonralimab or bevacizumab.\n* Active malignancy other than colorectal cancer within 5 years prior to first treatment.\n* Large tumor lesions, especially those previously irradiated, with signs of bleeding.\n* Imaging showing tumor invasion of major blood vessels (e.g., pulmonary artery or superior vena cava), including encasement or invasion of the vessel lumen.\n* Brain metastases (asymptomatic or treated symptomatic brain metastases stable for \\>4 weeks allowed).\n* Active autoimmune disease requiring systemic treatment.\n* Active pulmonary diseases such as tuberculosis, radiation pneumonitis, drug-induced pneumonitis, or severe pulmonary dysfunction during screening.\n* Requirement for long-term or high-dose NSAIDs (aspirin \\>325 mg) or anticoagulant therapy.\n* History of severe gastrointestinal events within 6 months prior to first treatment.\n* Severe intestinal obstruction symptoms or signs and unretrieved intestinal stents at screening.\n* Cardiovascular or cerebrovascular diseases including but not limited to: NYHA class \\> II heart failure; unstable or severe angina; myocardial infarction or stroke within 6 months; atrial fibrillation or other arrhythmias requiring treatment; symptomatic superior vena cava syndrome; prolonged QT interval (male QT \\> 450 ms; female QTc \\> 470 ms); uncontrolled hypertension despite medication (SBP \\>140 mmHg and\u002For DBP \\>90 mmHg) or history of hypertensive crisis or encephalopathy.\n* Known bleeding disorders or coagulopathies.\n* Uncontrolled pleural, pericardial, or ascitic effusions requiring drainage.\n* Active infection or unexplained fever \\>38.5°C at screening (cancer-related fever allowed).\n* Use of systemic broad-spectrum antibiotics within 30 days prior to first treatment.\n* Systemic corticosteroids (\\>10 mg prednisone equivalent daily) or immunosuppressants within 14 days prior to first treatment, or immunostimulants within 4 weeks.\n* Major surgery, severe fractures, or therapeutic clinical trials within 4 weeks prior to first treatment; herbal treatment within 2 weeks.\n* Ongoing adverse events from prior antitumor therapy greater than grade 1.\n* HIV infection, other congenital or acquired immunodeficiencies, or history of organ or allogeneic bone marrow transplantation (except corneal transplantation).\n* Positive hepatitis B surface antigen (HBsAg) and\u002For hepatitis B core antibody (HBcAb) with HBV DNA \\>10⁴ copies\u002FmL (\\~2000 IU\u002FmL); or positive hepatitis C antibody with HCV RNA \\>10³ copies\u002FmL; co-infection with HBV and HCV excluded.\n* Vaccination with live or attenuated vaccines within 30 days prior to first treatment.\n* Prior treatment with immune checkpoint inhibitors (e.g., anti-PD-1, anti-PD-L1, anti-CTLA-4, anti-OX-40, anti-CD137).\n* Prior adjuvant targeted therapy against EGFR, VEGF, or VEGFR (e.g., bevacizumab, cetuximab, panitumumab, apatinib, regorafenib, anlotinib).\n* Psychiatric disorders, epilepsy, dementia, or substance abuse that may affect compliance.\n* Other conditions or lab abnormalities that may interfere with study participation or confound results as judged by investigators or sponsors.",{"count":531,"type":22},22,[442],"This is a single-arm, multi-center, exploratory study evaluating the efficacy and safety of iparomlimab and tuvonralimab (QL1706) in combination with bevacizumab for the treatment of patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) unresectable or metastatic colorectal cancer. Eligible participants who meet the inclusion and exclusion criteria will provide written informed consent and receive QL1706 at 5.0 mg\u002Fkg and bevacizumab at 7.5 mg\u002Fkg on Day 1 of every 3-week cycle (Q3W), until disease progression or completion of 2 years of treatment. The primary endpoint of this study is objective response rate (ORR). Secondary endpoints include disease control rate (DCR), duration of response (DoR), progression-free survival (PFS), overall survival (OS), PFS and OS rates at 6, 12, and 24 months, and safety.",[535,536,537],"Unresectable Colorectal Cancer","Metastatic Colorectal Cancer (CRC)","MSI-H\u002FdMMR Colorectal Cancer",[539,540,541],"QL1706","CRC","MSI-H\u002FdMMR","2025-05-28",{"date":544,"type":37},"2025-06-06",{"date":546,"type":22},"2025-06-27",{"date":41,"type":22},{"name":43,"class":44},{"id":550,"slug":551,"hasResults":12,"nctId":552,"briefTitle":553,"officialTitle":554,"acronym":4,"eligibilityCriteria":555,"healthyVolunteers":169,"sex":17,"minAge":53,"maxAge":390,"enrollmentInfo":556,"targetDuration":4,"studyType":23,"phases":558,"briefSummary":559,"conditions":560,"keywords":563,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":564,"lastUpdatePostDateStruct":565,"startDateStruct":567,"completionDateStruct":569,"leadSponsor":571,"locationsCount":45},"100589744","phase-4-effect-of-opioid-free-anaesthesia-on-postoperative-delirium-in-elderly-patients-undergoing-gastrointestinal-surgery-100589744","NCT06958393","Effect of Opioid-free Anaesthesia on Postoperative Delirium in Elderly Patients Undergoing Gastrointestinal Surgery","Effect of Opioid-free Anaesthesia on Postoperative Delirium in Elderly Patients Undergoing Gastrointestinal Surgery: a Single-centre, Prospective, Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age ≥ 65 years\n2. American Society of Anesthesiologists (ASA) physical status classification I-III\n3. Scheduled for elective gastrointestinal surgery under general anaesthesia\n4. Body mass index (BMI) between 18.0 and 30.0 kg\u002Fm²\n\nExclusion Criteria:\n\n1. Refusal to undergo surgery\n2. Emergency surgery\n3. Language impairment or severe hearing or visual deficits that hinder effective communication with research or surgical staff\n4. History of neurological or psychiatric disorders, including Alzheimer's disease (AD), other forms of dementia, stroke, or psychosis\n5. Long-term use of psychotropic medications (e.g., clozapine, risperidone, olanzapine, haloperidol, chlorpromazine)\n6. Cardiac or craniocerebral surgery within the past year\n7. Participation in other interventional clinical studies within the past 3 months\n8. Preoperative cognitive impairment defined as a modified Telephone Interview for Cognitive Status (TICS-M) score ≤ 27\n9. Patients will only be enrolled once, even if a subsequent surgery related to the primary procedure is performed",{"count":557,"type":22},406,[57],"Background Postoperative delirium (POD) is a common acute and transient form of brain dysfunction in elderly patients following surgery that can lead to serious adverse clinical outcomes and even death. Although existing studies have preliminarily investigated the effects of opioid-free anaesthesia (OFA) on POD, high-quality evidence on these effects for elderly patients undergoing gastrointestinal surgery remains limited. This study aims to investigate the effects of OFA on the development of POD in elderly patients following gastrointestinal surgery.\n\nMethods and analysis:\n\nThis single-centre, prospective, randomized controlled trial will be conducted at the First Affiliated Hospital of Shandong First Medical University, China. A total of 406 patients aged 65 years or older who are scheduled for elective gastrointestinal surgery will be randomly allocated to receive either opioid-free anaesthesia (OFA; dexmedetomidine, esmolol, and esketamine) or conventional opioid-based anaesthesia (OBA). The primary outcome is the incidence of POD 7 days after surgery. The secondary outcomes are all-cause mortality within 30 days after surgery, intraoperative haemodynamic changes, the 15-item quality of recovery (QoR-15) scores at 24 h, 48 h, and 72 h after surgery, complications during postoperative hospitalization, pain numerical rating scale (NRS) score at 72 h after surgery, incidence of nausea and vomiting at 72 h after surgery, morphine milligram equivalent for analgesics at 72 h after surgery, duration of anaesthesia (from induction to discontinuation), duration of surgery (from skin incision to the last suture), duration of post-anaesthesia care unit (PACU) stay, and length of hospital stay.\n\nDiscussion:\n\nThe results of this study may shed light on the effects of OFA on POD in elderly patients undergoing gastrointestinal surgery. The study is designed on the basis of the following key hypothesis: the use of opioid drugs for anaesthesia may increase the risk of POD through mechanisms such as blood-brain barrier destruction, neuroinflammatory responses, and central nervous system depression. Through the single-centre and prospective design of this randomized controlled trial, this study will directly analyse differences in the effects of OFA and conventional OBA on the incidence of POD, haemodynamic stability and long-term cognitive function in elderly patients.\n\ngastrointestinal surgery.",[561,562],"Delirium - Postoperative","Opioid-Free Anaesthesia",[225,226,227,228],"2025-05-03",{"date":566,"type":37},"2025-05-06",{"date":568,"type":22},"2025-05-20",{"date":570,"type":22},"2026-05-12",{"name":43,"class":44},{"id":573,"slug":574,"hasResults":12,"nctId":575,"briefTitle":576,"officialTitle":577,"acronym":4,"eligibilityCriteria":578,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":579,"targetDuration":4,"studyType":23,"phases":581,"briefSummary":582,"conditions":583,"keywords":4,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":585,"lastUpdatePostDateStruct":586,"startDateStruct":588,"completionDateStruct":590,"leadSponsor":592,"locationsCount":45},"100470586","efficacy-and-safety-of-long-term-oral-staphylococcus-albicans-tablets-in-patients-with-bronchiectasis-100470586","NCT05407792","Efficacy and Safety of Long-term Oral Staphylococcus Albicans Tablets in Patients With Bronchiectasis","Efficacy and Safety of Long-term Oral Administration of Staphylococcus Albicans Tablets in Patients With Acute Exacerbation and Stable Bronchiectasis: a Multicenter, Prospective Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Patients with bronchiectasis diagnosed by clinical manifestations and chest HRCT according to the diagnostic criteria for bronchiectasis;\n\n  * Patients with idiopathic or post-infectious bronchiectasis;\n\n    * 18years old;\n\n      * Patients should have at least 2 acute exacerbations within 1 year before enrollment;\n\n        * Patients in either acute exacerbation or stable period can be included.\n\nExclusion Criteria:\n\n* Cystic fibrosis;\n\n  * Immunodeficiency, allergic bronchopulmonary aspergillosis, etc.;\n\n    * Traction bronchiectasis caused by severe emphysema or advanced pulmonary fibrosis;\n\n      * Still smoking;\n\n        * Complicated with asthma or chronic obstructive disease Lung;\n\n          * Patients with severe cardiovascular disease, severe neurological disease, or severe liver or kidney damage;\n\n            * Malignant tumors;\n\n              * Allergy to Staphylococcus albicans tablets;\n\n                * Patients with a history of gastric ulcer or intestinal malabsorption;\n\n                  * Pregnant or lactating women;\n\n                    * patients with poor compliance;\n\n                      * previous (within 6 months before the start of the study) or concurrently taking immunostimulating drugs (including thymosin, interferon, transfer factor, BCG, pneumonia vaccine and any kind of bacteria Extracts, such as Biostim, except for influenza vaccine) or immunosuppressants;\n\n                        * Patients who are participating in or have participated in interventional clinical trials within 3 months.",{"count":580,"type":22},134,[25],"The main purpose of this study is to investigate whether long-term oral administration of Staphylococcus albicans tablets can significantly reduce the number of acute exacerbations in patients with bronchiectasis. Secondary objective is to explore whether long-term oral administration of Staphylococcus albicans tablets can reduce the risk of hospitalization in patients with bronchiectasis and whether it can improve the quality of life of patients. Other purpose is to explore the regulatory effect of long-term oral administration of Staphylococcus albicans tablets on the immune function of patients with bronchiectasis.",[584],"Bronchiectasis","2025-02-26",{"date":587,"type":37},"2025-02-28",{"date":589,"type":37},"2022-06-06",{"date":591,"type":22},"2026-12-31",{"name":43,"class":44},{"id":594,"slug":595,"hasResults":12,"nctId":596,"briefTitle":597,"officialTitle":597,"acronym":4,"eligibilityCriteria":598,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":170,"enrollmentInfo":599,"targetDuration":4,"studyType":118,"phases":4,"briefSummary":601,"conditions":602,"keywords":4,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":604,"lastUpdatePostDateStruct":605,"startDateStruct":607,"completionDateStruct":609,"leadSponsor":611,"locationsCount":45},"100574030","efficacy-and-safety-of-triple-targeted-drug-therapy-in-treatment-naive-patients-with-non-low-risk-pah-a-real-world-multicenter-study-100574030","NCT06753981","Efficacy and Safety of Triple-targeted Drug Therapy in Treatment-naive Patients With Non-low-risk PAH: A Real-world, Multicenter Study","Inclusion Criteria:\n\n* Consent and sign the informed consent form\n* Non-low-risk PAH treatment-naive patients\n\nExclusion Criteria:\n\n* Positive acute vascular response test for idiopathic\u002Fhereditary\u002Fdrug-related arterial pulmonary hypertension\n* Pulmonary veno-occlusive disease\u002Fpulmonary capillary hemangiomatosis (PVOD\u002FPCH) with arterial pulmonary\n* Pregnant or lactating women\n* Suffering from mental illness or cognitive impairment\n* PAH patients with concurrent malignant tumors\n* Patients with moderate to severe hepatic impairment, renal impairment, and severe anemia\n* Currently participating in other interventional clinical studies\n* Key clinical data is incomplete, or the investigator considers that the patient has other factors that make them unsuitable for this study.",{"count":600,"type":22},48,"This study is a multicenter, prospective, observational study aimed at investigating the efficacy and safety of triple targeted drug therapy in patients with arterial pulmonary hypertension (PAH) who are not at low risk and are receiving initial treatment. The prognosis of arterial pulmonary hypertension is explored.",[603],"Arterial Pulmonary Hypertension (PAH)","2024-12-22",{"date":606,"type":37},"2024-12-31",{"date":608,"type":37},"2024-12-10",{"date":610,"type":22},"2027-02-14",{"name":43,"class":44},{"id":613,"slug":614,"hasResults":12,"nctId":615,"briefTitle":616,"officialTitle":617,"acronym":4,"eligibilityCriteria":618,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":619,"targetDuration":4,"studyType":23,"phases":621,"briefSummary":622,"conditions":623,"keywords":628,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":632,"lastUpdatePostDateStruct":633,"startDateStruct":635,"completionDateStruct":637,"leadSponsor":638,"locationsCount":4},"100572662","phase-4-the-cardioprotective-effects-of-improving-potassium-variability-in-maintenance-hemodialysis-patients-100572662","NCT06736184","the Cardioprotective Effects of Improving Potassium Variability in Maintenance Hemodialysis Patients","A Prospective Multicenter Randomized Controlled Trial on the Cardioprotective Effects of Improving Potassium Variability in Maintenance Hemodialysis Patients","Inclusion Criteria:\n\n1. Age 18-75 years old;\n2. Maintenance hemodialysis ≥3 months;\n3. Serum potassium ≥5.0mmol\u002FL and ≤8mmol\u002FL before dialysis;\n4. Have independent ability;\n5. Complete clinical baseline data.\n\nExclusion Criteria:\n\n1. Complicated with congenital heart disease, myocardial infarction and other heart diseases that may lead to cardiac dysfunction;\n2. Combined with other serious diseases, such as immune diseases, severe liver and kidney dysfunction;\n3. Unable to cooperate with the researcher due to mental reasons;\n4. If the duration of dialysis is less than 4 hours, severe infection;\n5. Patients with malignant tumors or major mental disorders;\n\n6, except primary cardiomyopathy;\n\n7\\. Severe constipation, intestinal obstruction, etc.\n\n8\\. other investigators considered that enrollment was not recommended.",{"count":620,"type":22},100,[57],"The management of serum potassium in maintenance hemodialysis（MHD ）patients is one of the hot topics at present. In order to control hyperkalemia in dialysis patients, the use of hypokalemic dialysate is the most important measure to reduce potassium. This measure effectively reduces serum potassium, but increases the risk of hypokalemia after dialysis, which increases the risk of all-cause death in patients. Hyperkalemia and hypokalemia during and at the end of dialysis are important factors for arrhythmia and death in MHD patients. Due to the intermittent nature of hemodialysis treatment, MHD patients often experience frequent fluctuations in serum potassium, which is a potential risk factor for poor prognosis of MHD patients. Serum potassium variability can better reflect the potassium homeostasis in MHD patients. In addition to hyperkalemia and hypokalemia, serum potassium variability is a potential risk factor affecting the prognosis of MHD patients. At present, there are few studies on the effect of improving serum potassium variability on cardiovascular complications, especially multi-center randomized controlled trials. In this study, sodium zirconium cyclosilicate was used to control hyperkalemia before dialysis and increase potassium concentration in dialysate, so as to reduce the risk of hypokalemia after dialysis, and to verify whether improving serum potassium variability can reduce myocardial injury in hemodialysis patients.",[624,625,626,627],"Chronic Kidney Disease on Hemodialysis","Hypokalemia","Hyperkalemia","Myocardial Injury",[629,630,631],"maintenance hemodialysis","Potassium Variability","Myocardial injury","2024-12-12",{"date":634,"type":37},"2024-12-16",{"date":636,"type":22},"2025-03-01",{"date":591,"type":22},{"name":43,"class":44},""]